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ytes) have
been proposed to play a significant and perhaps determining role in the expres-
sion of a cell-mediated response to neuroantigens (1-4). To test this preen
e prepared Fl-to-parent bone marrow chimeras and used these chimeras
as recipients in the adoptive transfer of experimental allergic encephalomyelitis
(EAE). Our results indicate that the development of EAE within the recipient is
dependent upon MHC compatibility between adoptively transferred lymphocytes
and bone marrow-derived cells. MHC compatibility between transferred lym-
phocytes and non-bone marrow-derived cells was not a requirement for adoptive
transfer of clinical disease.
Materials and Methods
Animals.
￿
Inbred Lewis [LEW (RT-1 ')] Brown Norway [BN (RT-1")], Fischer-344 [F-
344 (RT-1'"')], Buffalo [BUF (RT-Ib)], and ACI (RT-la) rat strains were obtained from
Microbiological Associates, Walkersville, MD, and from Simonson Laboratories, Inc.,
Gilroy, CA. The following (LEW X Parent-2)F, rat strains were bred and maintained
locally: (LEW X BN)F, (RT-1'/"), (LEW X BUFF, (RT-1'n'), and (LEW X ACI)F, (RT-
1'/a). Animals were provided access to food and waterwithout restriction and were watered
by hand during periods of paralysis.
Purification ofMyelin Basic Protein.
￿
Guinea pig brains were purchased from Pel-Freez
Biologicals (Rogers, AR) and stored at -70°C until extracted for basic protein (BP). BP
was prepared according to a procedure modified from Diebler et al. (5).
Immunization with BP-CFA.
￿
Myelin BP was rehydrated in saline at a concentration of
1 mg/ml and emulsified in an equal volume of CFA containing 10 mg/ml of nonviable,
dessicated Mycobacterium tuberculosis H37 RA. Active immunization with BP was accom-
plished by injecting 0.1 ml of the BP-CFA divided equally between the two front foot
pads.
Adoptive Transfer ofEAE.
￿
The procedure was followed as described (7).
Production of Bone Marrow Chimeric Animals.
￿
Animals received 900-1,000 rad of
irradiation using a "Cobalt source. After irradiation, hematopoietic function was restored
by bone marrow reconstitution. Chimeric rats were used as recipients not sooner than 6
mo after bone marrow engraftment.
Irradiation ofCell Recipients.
￿
Where indicated, cell recipients received 900-1,000 rad
of irradiation using a "Cobalt source 24 h before cell transfer.
Clinical Evaluation.
￿
Rats used in adoptive transfer experiments were evaluated daily
for clinical signs of neurologic impairment and graded on a scale of 1-3: animals with
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Donor*
TABLE I
MHCRestriction ofAdoptively Transferred EAE
en a
Histology.
￿
Tissue wasremoved
disease. Afterfixation in 10%buffere
isolated from thesurrounding
embedded in paraffin. At least
hematoxylin andeosin.
LEW
(ACI x LEW)F,
* Spleen cells were obtained from donors 12-14 d after BP-CFA immunization. Cells were cultured in the
presence ofBP for 72 h and were subsequently transferred to recipients.
t Recipients received 2 X 107 cells.
f MHC haplotypes ofrecipient animals areas follows; LEW, RT-1'; F-344, RT-I'"'; BN, RT-I"; BUF, RT-Ib.
t Irradiated recipients received 900-1,000 rod ofirradiation 24 h before cell transfer.
Number ofanimalswithclinical signs ofdisease pertotal animalspergroup; clinicaldisease indices aredescribed
in Materialsand Methods.
** Average maximum cli
ess or paralysis were
continencewas givenagrade 3.
drecipients atthetimeofmaximumclinical
rmaldehydesolutions,spinal cordswere carefully
e. Thecords weresubdividedinto threesegmentsand
ght sections were cut from each blockand stained with
Results and Discussion
The adoptive transfer of clinical EAE is readily achieved with spleen cells
obtained from BP-sensitized donors if these cells are stimulated in vitro with
specific antigen before transfer. Table I shows the development of adoptively
transferred clinical EAE in syngeneic and semisyngeneic, but not allogeneic
recipients ofBP-stimulated spleen cellsobtained from BP-CFA-immunized Lewis
(LEW) and (ACI X LEW)F1 rats. These results are consistent with other reports
of MHC restriction in the transfer of EAE in the rat (6, 7). In addition to
exhibiting arequirement for MHC compatibility, presumably reflectingthe need
for in vivoantigen presentation requirements, transferred cells must escape host
rejection mechanisms during the inductive phase of the disease. For example,
clinical EAE develops in experiments where LEW cells are transferred to F344
rats or (LEW X BN)F, cells are transferred to LEW rats only if the recipient is
irradiated before transfer. While these donor-recipient combinations have shared
MHC antigens, recipient recognition of foreign non-MHC antigens on the
transferred cells apparently inhibits donor cell function in the nonirradiated
recipient. Irradiation of recipients before transfer, however, does not allow
MHC-incompatible cells to transfer EAE, indicating a requirement for proper
antigen presentation within the recipient.
The restriction patterns seen in Table I do not separate the APC role of la',
nonhematogenouscells from that ofthe bone marrow-derived mononuclearcell
populations in the development of adoptively transferred EAE. The data pre-
RecipientU
Nonirradiated
Disease/total Symptoms**
Irradiatedt
Disease/total Symptoms**
LEW 8/8 2.7 6/6 2.8
BN 0/4 0.0 0/4 0.0
BUF 0/4 0.0 0/4 0.0
F-344 0/6 0.0 6/6 2.7
(BN X LEW)F, 6/6 2.6 5/5 2.4
(ACI X LEW)F, 7/7 2.8 6/6 2.6
(ACI X LEW)F, 6/6 2.4 5/5 2.6
LEW 0/7 0.0 6/6 2.7
ACI 0/5 0.0 6/6 2.2
BN 0/4 0.0 0/4 0.01908
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TABLE II
Adoptive Transfer EAE in Bone Marrow Chimeras
* Spleen cells were obtained from donors 12-14 d after BP-CFA immunization. Cells were
cultured in the presence of BP for 72 h and were subsequently transferred to recipients.
$ Recipients received 2 X 10' cells.
Number of animals with clinical signs of disease per total animals per group; clinical
disease indices are described in Materials and Methods.
Average maximum clinical signs that develop after disease onset.
' Average time ofonset (days) ofgrade 2 clinical signs.
** Average time (days) at which recovery from clinical disease was complete.
sented in Table II demonstrate that (LEW X BN)F1-*BN bone marrow chimeras
developed clinical signs of disease after transfer of LEW cells similar to those
seen with syngeneic transfer of BP-activated LEW spleen cells. In contrast,
transfer of allogeneic (ACI) BP-activated spleen cells to these bone marrow
chimeras did not result in clinical or histopathologic signs of EAE. However,
(ACI X LEW)F1-SLEW bone marrow chimeras developed clinical disease when
infused with BP-reactive ACI-derived spleen cells. In all cases, histologic disease
routinely associated with clinical EAE (8) was evident in animals that had
exhibited signs of clinical disease (results not shown).
The chimeras used in this study were designed to test the potential influence
ofnon-bone marrow-derivedcellson the development ofadoptively transferred
EAE. Endothelial cells isolated from the cerebral vasculature express la when
isolated from SJL mice exhibiting clinical EAE, but Ia+ endothelial cells are not
found in similar preparations from normal syngeneic mice (1). In guinea pigs
immunized with BP, endothelial cells become Ia+ just before disease onset (9).
However, in (Strain 2 X Strain 13)1`1 hybrids, only the high-responder strain 13
haplotype is expressed on endothelial cells of BP-sensitized guinea pigs (10).
Large numbers of Ia' cells are also found in multiple sclerosis brain lesions,
especially in the peripheral areas ofthe expanding plaque (11). These observa-
tions have led some investigators to suggest that endothelial cells may have a
relevant role in antigen presentation in vivo (9, 12), making them an active and
central participant in the expression ofantigen-specific delayed-type hypersensi-
tivity responses (13) in general and in the development of the autoimmune
response to antigens ofthe central and peripheral nervous tissue.
Our results question the need for MHC-restricted antigen presentation by
endothelial cells in vivo. Table I shows that LEW donor cells transfer clinical
EAE only to recipients that share the LEW MHC and that the (LEW X BN)F1
recipient develops a severity ofclinical disease similar to that seen with syngeneic
recipients. In recipients that develop disease, antigen presentation could be the
responsibility of endothelial cells or astrocytes as well as bone marrow-derived
Donor* Recipient* Disease/totals Symptoms)
Dis-
ease'
onset
Disease**
recovery
LEW LEW 6/6 2.6 5.2 8.1
LEW (LEW X BN)F,~BN 11/11 2.7 5.4 8.5
Bone marrow chimera
LEW BN 0/4 0.0 - -
ACI ACI 4/4 2.2 5.5 8.2
ACI (ACI X LEW)F,-SLEW 5/6 2.4 5.3 8.3
Bone marrow chimera
ACI (LEW X BN)F,~BN 0/3 0.0 - -
Bone marrow chimeraHINRICHS ET AL.
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TABLE III
Persistence ofDonor Derived BP Sensitive Cells in Bone Marrow Chimeras
s Spleen cells were obtained from donors 12-14 d after BP-CFA immunization. Cells were cultured in the presence
of BP for 72 h and were subsequently transferred to recipients.
t Recipients received 2 x 10' cells. All were bone marrow chimera.
Spleen cells were obtained from primary recipients 10-21 d after recovery from the initial episode of clinical
disease. The cells were cultured with BP for 72 h before transfer to secondary recipients.
Number of animals with clinical signs of disease per total animals per group; clinical disease indices are described
in Materials and Methods.
' Average maximum clinical signs that develop after disease onset.
cells. However, chimeric recipients of the (LEW x BN)F,-+BN construct would
possess non-bonemarrow-derived cells allogeneicto thetransferred LEW spleen
cells. Since Table II shows that these chimeric recipients develop and recover
from clinical disease with the same kinetics as syngeneic recipients, any MHC-
restricted antigen-presenting function by these non-bone marrow-derived cells
is not required for the development ofadoptively transferred EAE.
We have previously shown (7) that rats that have recovered from adoptively
transferred EAE can serve as a source of transfer-active cells and that this
transfer-active population is derived from the original donor cell inoculum. It is
evident from the data presented in Table II that recovery from adoptively
transferred clinical disease in the BN chimeras is temporally consistent with
recovery after syngeneic transfer of clinical disease. Furthermore, spleen cells
obtained from chimeric recipients of transfer-active LEW cells can serve as a
population of transfer-active cells (Table III). Notably, serial transfer of EAE by
this cell population is still dependent on in vitro activation by spleen cells. The
recipient combinations exhibiting successful serial transfer ofclinical disease also
suggest that BP-specific LEW cells survive in the chimeric environment and can
subsequently transfer clinical disease to LEW recipients. In contrast, serial
transfer to BN or ACI recipients was not successful. These latter results also
support our previous observations (7) that the development ofadoptively trans-
ferred EAE does not result in the recruitment ofBP-reactive cells derived from
the recipient's lymphoid compartment.
If the endothelium does not play an active, antigen-presenting role in the
development of EAE, how then does the inflammatory lesion develop? The
ability to transfer EAE to a recipient in which the endothelium is allogeneic to
the transferredcellsmay beexplained byaninteraction ofT cells, Tcell products,
and mast cells (14-17). In support ofthis model we (18) and others (19-22) have
reported that the clinical signs of EAE can be prevented in animals that have
received compounds that alter mast cell release ofhistamine and serotonin.
In addition to lending indirect support of the Askenase-Loveren model of
DTH (17), our results would also suggest that the clinical development of EAE
is not caused by the direct interaction of MHC-restricted cytotoxic cells and
central nervous system (CNS) tissue. The response ofchimeric recipients to the
Donor*
Primary
Recipient=
Secondary
Culture#
Secondary
Recipient Disease'/total Symptoms'
LEW (LEW x BN)F,-sBN BP LEW 4/4 2.2
(LEW x BN)F,~BN BP BN 0/4 0.0
(LEW x BN)F,~BN - LEW 0/4 0.0
LEW (ACI x LEW)F,-.ACI BP LEW 4/4 2.4
(ACI x LEW)F,~ACI BP ACI 0/3 0.0
(ACI x LEW)F,~ACI BP ACI; 0/4 0.0191 0
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transfer of BP-specific lymphocytes (Table II) indicates that the presence of
semisyngeneic F, bone marrow-derived accessory cells are sufficient for disease
induction, even though the transferred lymphocytes are allogeneic to the CNS.
In these donor-recipient combinations the only possible MHC compatibility is
with the transferred lymphocytes and the established bone marrow. Non-bone
marrow-derived -CNS tissue would not display MHC compatibility with the
transferred lymphocytes. Consequently, MHC-restricted cytotoxic cells would
not be expected to function in the development of clinical disease.
Our observation that the endothelium need not be MHC compatible with BP-
specific lymphocytes to have these cells function in vivo may be relevant to
general considerations of the role of Ia+, non-bone marrow-derived cells and
the antigen-presenting requirement for delayed-type hypersensitivity responses.
It is probable within the syngeneic system that all Ia' cells, independent of origin,
are involved in antigen presentation at some point in the immune response.
However, the results of our studies would argue that any antigen-presenting
function of endothelial cells in vivo is secondary to that of bone marrow-derived
cells and that the development of EAE is not influenced by the lack of antigen
presentation, or of compatible Ia+ expression, by cells of the endothelial barrier.
Summary
The adoptive transfer of clinical and histopathologic signs of experimental
allergic encephalomyelitis (EAE) requires MHC compatibility between cell donor
and cell recipient. The results of adoptive transfer studies using F, to parent
bone marrow chimeras as recipients of parental-derived BP-sensitive spleen cells
indicate that this restriction is not expressed at the level of the endothelial cell
but is confined to the cells ofbone marrow derivation. Furthermore, these results
indicate that the development of EAE is not dependent on the activity of MHC-
restricted cytotoxic cells.
Receivedfor publication 15July 1987 and in revisedform 4 September 1987.
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